In this issue:
25-year trends in cancer incidence among adults 35-69 years
Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for NSCLC
Cancer in Victorian prisoners
Complete cancer prevalence in Europe in 2020 by disease duration and country
Use of chemotherapy in patients with cancer across eight sites
Use of radiotherapy in patients with cancer across eight sites
Nivolumab in patients with genetic alterations in DNA damage and repair
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
Clinical outcomes and safety of ICIs in patients with solid tumours
CNS efficacy of osimertinib with or without chemotherapy for NSCLC
Please login below to download this issue (PDF)